Sai Life Sciences Limited
₹522 - ₹549
27
10.26
| Open Date: | 11-Dec-2024 |
| Close Date: | 13-Dec-2024 |
| Allotment Date: | 16-Dec-2024 |
| Listing Date: | 18-Dec-2024 |
| Listing Price: | ₹650/- |
| Face Value: | ₹₹1 per share Per Equity Share |
| Issue Price: | ₹₹522 to ₹549 per share Per Equity Share |
| Issue Size: | 55,421,123 shares (aggregating up to ₹3,042.62 Cr) |
| Market Lot (Min Amount): | 27 share (₹14,823) |
| Earning Per Share(EPS) | ₹13.96/- |
| P/E Ratio | N/A |
| RoNW | 105.31% |
| Net Asset Value (NAV) - Post Issue: | ₹N/A/- |
| Total Assets | Total Revenue | Profit After Tax | |
|---|---|---|---|
| 31 Mar,2024 | 2,275.14 | 1,494.27 | 82.81 |
| 31 Mar,2023 | 2,186.65 | 1,245.11 | 9.99 |
| 31 Mar,2022 | 2,164.23 | 897.74 | 6.23 |
| Pre Issue Share Holding | N/A% |
| Post Issue Share Holding | N/A% |
| 1. Kanumuri Ranga Raju |
| 2. Krishnam Raju Kanumuri |
| 3. Kanumuri Mytrey |
| 4. Sai Quest Syn Private Limited |
| 5. Sunflower Partners |
| 6. Lily Partners |
| 7. Marigold Partners |
| 8. Tulip Partners |
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.